The present disclosure provides novel gene therapy constructs comprising a PARK2 gene or activating variant and methods of administering to treat Parkinson's Disease or symptoms thereof.
GENE THERAPY DELIVERY OF PARKIN MUTANTS HAVING INCREASED ACTIVITY TO TREAT PARKINSON'S DISEASE